This factsheet provides a useful summary of non-small cell lung cancer (NSCLC). You will find valuable insights into epidemiology data, risk factors, symptoms, prognosis, diagnosis, and management and treatment options, all in an easy-to-read, downloadable format.
Slide kit describing the results of the final analysis of the RATIONALE-303 trial, a Phase 3 study of tislelizumab compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC).
The RATIONALE-307, RATIONALE-304, and RATIONALE-303 trials were designed to evaluate the safety and efficacy of tislelizumab as a monotherapy and in combination with chemotherapy for the treatment of non-small cell lung cancer (NSCLC).
Download this factsheet to review the study design and key efficacy and safety takeaways.
